Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and tolerability of single doses of SBI-087 in subjects with rheumatoid arthritis.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Collaborator: Emergent Product Development Seattle LLC

Criteria

Inclusion Criteria:

• Man or nonlactating and nonpregnant woman, aged 18 to 70 years, inclusive, at the screening visit.

• Must meet criteria for rheumatoid arthritis with functional class I to III.

• Diagnosis of rheumatoid arthritis more than 6 months before study day 1 and rheumatoid arthritis onset after 16 years of age

Exclusion Criteria:

• Any significant health problems other than rheumatoid arthritis.

• Treatment of greater than 10 mg of prednisone per day.

• Treatment with cyclophosphamide.